Evidence map›Paper›PMID 36072788›Full record

ArticleFrontiers in oncology2022

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma.

Krishnendu Pal, Tabish Hussain, Hao Xie, Shenduo Li, Ping Yang, Aaron Mansfield, Yanyan Lou, Shantanu Chowdhury, Debabrata Mukhopadhyay

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Krishnendu PalDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, United States.
Tabish HussainGenomics and Molecular Medicine Unit, CSIR-Institute of Genomics and Integrative Biology, Mathura Road, New Delhi, India.
Hao XieDivision of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
Shenduo LiDivision of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, United States.
Ping YangDepartment of Quantitative Health Sciences, Mayo Clinic Scottsdale, AZ, United States.
Aaron MansfieldDivision of Medical Oncology, Mayo Clinic, Rochester, MN, United States.
Yanyan LouDivision of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, United States.
Shantanu ChowdhuryIntegrative and Functional Biology Unit, CSIR- Institute of Genomics and Integrative Biology, New Delhi, India.
Debabrata MukhopadhyayDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Jacksonville, FL, United States.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USWinnMed · USAcademy of Scientific and Innovative Research · INInstitute of Genomics and Integrative Biology · IN

Funding

Targeting Pancreatic Cancer Using Peptide Chemistry: From Bench to BedsideR01CA150190 · NCI · MAYO CLINIC ROCHESTER · PI MIERKE, DALE F, MUKHOPADHYAY, DEBABRATA · 2010 to 2021
$5.7M
Regulatory Pathways and Role of VPF/VEGF in Renal CancerR01CA078383 · NCI · MAYO CLINIC ROCHESTER · PI MUKHOPADHYAY, DEBABRATA · 2004 to 2019
$4.5M
REGULATORY PATHWAYS AND ROLE OF VPF/VEGF IN RENAL CANCERR29CA078383 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI MUKHOPADHYAY, DEBABRATA · 1998 to 2002
$383k
NCI NIH HHS R01 CA078383NCI NIH HHS R01 CA150190NCI NIH HHS R29 CA078383
6 · The paper itself

Abstract

Objective: The objective of this study is to evaluate the expression of different nicotinic acetylcholine receptors (nAChRs), programmed death ligand-1 (PD-L1), and dopamine receptor D2 (DRD2) as prognostic factors in lung cancer and any correlation among them. Since all of the above genes are typically upregulated in response to smoking, we hypothesized that a correlation might exist between DRD2, PD-L1, and nAChR expression in NSCLC patients with a smoking history and a prediction model may be developed to assess the clinical outcome. Methods: We retrospectively analyzed samples from 46 patients with primary lung adenocarcinoma who underwent surgical resection at Mayo Clinic Rochester from June 2000 to October 2008. The expression of PD-L1, DRD2, CHRNA5, CHRNA7, and CHRNA9 were analyzed by quantitative PCR and correlated amongst themselves and with age, stage and grade, smoking status, overall survival (OS), and relapse-free survival (RFS). Results: Only PD-L1 showed a statistically significant increase in expression in patients older than 65. All the above genes showed higher expression in stage IIIB than IIIA, but none reached statistical significance. Interestingly, we did not observe significant differences among never, former, and current smokers, but patients with pack years greater than 30 showed significantly higher expression of CHRNA9. We observed a strong positive correlation between PD-L1/DRD2, PD-L1/CHRNA5, and CHRNA5/CHRNA7 and a weak positive correlation between DRD2/CHRNA5 and DRD2/CHRNA7. Older age was independently associated with poor OS, whereas lower CHRNA7 expression was independently associated with better OS. Conclusions: We observed strong positive correlations among PD-L1, DRD2, and some of the nAChRs. We investigated their prognostic significance in lung cancer patients and found CHRNA7 to be an independent prognostic factor. Overall, the results obtained from this preliminary study warrant a large cohort-based analysis that may ultimately lead to potential patient-specific stratification biomarkers predicting cancer-treatment outcomes.

Indexed as

DRD2lung cancernAChRNSCLCPD-L1smoking

Identifiers

PMID36072788
PMCPMC9441878
OpenAlexW4292590396

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.